CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES

被引：0
|
作者：
de Botton, S. [1 ]
Pollyea, D. A. [2 ]
Stein, E. M. [3 ]
DiNardo, C. [4 ]
Fathi, A. T. [5 ]
Roboz, G. J. [6 ]
Collins, R. [7 ]
Swords, R. T. [8 ]
Flinn, I. [9 ]
Altman, J. K. [10 ]
Tallman, M. S. [3 ]
Kantarjian, H. [4 ]
Colby, K. [11 ]
Fan, B. [11 ]
Goldwasser, M. [11 ]
Prahl, M. [11 ]
Agresta, S. [11 ]
Stone, R. M. [12 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[8] Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[11] Agios Pharmaceut, Cambridge, MA 02139 USA
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P563
引用
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [1] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
    Pollyea, D. A.
    de Botton, S.
    Fathi, A. T.
    Stein, E. M.
    Tallman, M. S.
    Agresta, S.
    Bowden, C.
    Fan, B.
    Prah, M.
    Yang, H.
    Yen, K.
    Stone, R. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195
  • [2] PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
    Fan, B.
    Chen, Y.
    Wang, F.
    Yen, K.
    Utley, L.
    Prahl, M.
    Colby, K.
    Straley, K.
    Bowden, C.
    Biller, S.
    Agresta, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 218 - 218
  • [3] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
    Fan, Bin
    Le, Kha
    Manyak, Erika
    Liu, Hua
    Prahl, Malia
    Bowden, Chris J.
    Biller, Scott
    Agresta, Sam
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [4] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
    Popovici-Muller, Janeta
    Lemieux, Rene M.
    Artin, Erin
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Travins, Jeremy
    Cianchetta, Giovanni
    Cai, Zhenwei
    Zhou, Ding
    Cui, Dawei
    Chen, Ping
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    David, Muriel D.
    Penard-Lacronique, Virginie
    Quivoron, Cyril
    Saada, Veronique
    De Botton, Stephane
    Gross, Stefan
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Kim, Hyeryun
    Jin, Shengfang
    Gu, Zhiwei
    Yao, Gui
    Luo, Zhiyong
    Lv, Xiaobing
    Fang, Cheng
    Yan, Liping
    Olaharski, Andrew
    Silverman, Lee
    Biller, Scott
    Su, Shin-San M.
    Yen, Katharine
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
  • [5] Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
    Le, Kha
    Wada, Russ
    Dai, David
    Fan, Bin
    Liu, Guowen
    Liu, Hua
    Attar, Eyal C.
    Agresta, Samuel V.
    Yang, Hua
    BLOOD, 2018, 132
  • [6] Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations
    Popovici-Muller, Janeta
    Lemieux, Rene
    Saunders, Jeffrey
    Salituro, Francesco
    Yen, Katharine
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    Gross, Stefan
    Artin, Erin
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Olaharski, Andrew
    Silverman, Lee
    Agresta, Sam
    Su, Michael
    Biller, Scott
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [7] Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
    DiNardo, Courtney D.
    de Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Swords, Ronan T.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Collins, Robert
    Altman, Jessica K.
    Flinn, Ian W.
    Mannis, Gabriel N.
    Mims, Alice S.
    Foran, James M.
    Pigneux, Arnaud
    Prince, Gabrielle T.
    Uy, Geoffrey L.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Liu, Hua
    Attar, Eyal C.
    Sacolick, Jennifer
    Yen, Katharine
    Hurov, Jonathan B.
    Choe, Sung
    Wu, Bin
    Stone, Richard M.
    BLOOD, 2016, 128 (22)
  • [8] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
    Mellinghoff, Ingo K.
    Touat, Mehdi
    Maher, Elizabeth
    De la Fuente, Macarena
    Cloughesy, Timothy F.
    Holdhoff, Matthias
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Huang, Ray
    Young, Robert J.
    Ellingson, Benjamin
    Nimkar, Tara
    Jiang, Liewen
    Ishii, Yuko
    Choe, Sung
    Fan, Bin
    Steelman, Lori
    Yen, Katharine
    Bowden, Chris
    Pandya, Susan
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2017, 19 : 10 - 11
  • [9] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
    DiNardo, Courtney
    de Botton, Stephane
    Pollyea, Daniel A.
    Stein, Eytan M.
    Fathi, Amir T.
    Roboz, Gail J.
    Collins, Robert
    Swords, Ronan T.
    Flinn, Ian W.
    Altman, Jessica K.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Derti, Adnan
    Goldwasser, Meredith
    Prahl, Malia
    Wu, Bin
    Yen, Katherine
    Agresta, Sam
    Stone, Richard M.
    BLOOD, 2015, 126 (23)
  • [10] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    De Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Mims, Alice S.
    Pollyea, Daniel A.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert H.
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, Will
    Pigneux, Arnaud
    Fathi, Amir T.
    Stein, Anthony S.
    Erba, Harry P.
    Prince, Gabrielle T.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Yen, Katharine
    Kapsalis, Stephanie M.
    Liu, Hua
    Goldwasser, Meredith
    Agresta, Sam
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
12345